Signal Transduct Target Ther November 2021 PMID 34776511

KRAS mutation: from undruggable to druggable in cancer.

Lamei Huang, Zhixing Guo, Fang Wang, Liwu Fu

Full text PDF Download social card

Mentions

Peak: 1 in Nov 2021

across 4 sources since Nov 2021

Extended reach

1,559

potential audience

Total likes

Video views

Mentions per month

Nov 2021 – Aug 2023

Where it's discussed

News41 articles
Blogs3 articles
X / Twitter2 posts
YouTube1 videos

AI synopsis

What people are saying

Participants widely acknowledge the progress from 'undruggable' to 'druggable' with examples like KRAS G12C inhibitors such as sotorasib, using words like 'game-changing' and 'hopeful' to emphasize their importance. The tone varies from optimistic to analytical, with many illustrating their points by referencing the underlying mechanisms and resistance challenges discussed in the publication.

AgreementModerate agreement

Most discussions express strong support and optimism regarding the breakthroughs in targeting KRAS mutations, emphasizing the significance of new drug developments like sotorasib.

InterestHigh interest

Posts demonstrate high curiosity about the topic, frequently mentioning specific inhibitors and implications for future treatments.

EngagementModerate engagement

Many comments delve into details about mechanisms, resistance, and the promise of combined therapies, showing active engagement.

ImpactHigh impact

The discussions highlight a perception that these advances could lead to meaningful clinical outcomes, potentially transforming cancer treatment.

Abstract in brief

KRAS is a key gene involved in many cancers and has historically been considered very difficult to target with drugs, earning the label "undruggable."
Recent advances, especially the development of KRAS G12C inhibitors like sotorasib and adagrasib, have shown promising results, with sotorasib becoming the first approved drug targeting KRAS G12C.
The review discusses new insights into KRAS's role in cancer, mechanisms of resistance to these new drugs, and strategies for combining treatments to improve personalized cancer therapy.]

Read the full abstract

All mentions

Advances in Targeting KRAS Mutations in Cancer Therapy

KRAS, a key gene involved in many cancers, was once considered undruggable. Recent developments like KRAS G12C inhibitors such as sotorasib have shown promising results, marking significant progress in personalized…

Medicine RTCL TV · Aug 3, 2023 20 views

filippo masini

@filimasini · X

KRAS mutation: from undruggable to druggable in cancer https://t.co/vPirmXRTPs

Dec 25, 2021 · 770 followers View post →